Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis
Duarte et al.,
Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity..,
Infectious Agents and Cancer, doi:10.1186/s13027-021-00406-y
Retrospective 199 prostate cancer patients hospitalized with COVID-19 in Brazil, showing no significant difference in mortality with active ADT.
risk of death, 11.2% lower, RR 0.89, p = 0.37, treatment 100 of 156 (64.1%), control 32 of 43 (74.4%), NNT 9.7, adjusted per study, odds ratio converted to relative risk.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Duarte et al., 25 Nov 2021, retrospective, Brazil, peer-reviewed, 4 authors.
Abstract: (2021) 16:66
Duarte et al. Infectious Agents and Cancer
https://doi.org/10.1186/s13027-021-00406-y
Open Access
RESEARCH ARTICLE
Impact of androgen deprivation therapy
on mortality of prostate cancer patients
with COVID‑19: a propensity score‑based
analysis
Mateus Bringel Oliveira Duarte1,2, Frederico Leal1, Juliana Luz Passos Argenton3 and
José Barreto Campello Carvalheira1*
Abstract
Background: Previous studies hypothesized that androgen deprivation therapy (ADT) may reduce severe acute
respiratory syndrome coronavirus 2 (SARS-COV2) infectivity. However, it is unknown whether there is an association
between ADT and a higher survival in prostate cancer patients with COVID-19.
Methods: We performed a retrospective analysis of prostate cancer (PC) patients hospitalized to treat COVID-19 in
Brazil’s public health system. We compared patients with the active use of ADT versus those with non-active ADT, past
use. We constructed propensity score models of patients in active versus non-active use of ADT. All variables were
used to derive propensity score estimation in both models. In the first model we performed a pair-matched propensity score model between those under active and non-active use of ADT. To the second model we initially performed
a multivariate backward elimination process to select variables to a final inverse-weight adjusted with double robust
estimation model.
Results: We analyzed 199 PC patients with COVID-19 that received ADT. In total, 52.3% (95/199) of our patients were
less than 75 years old, 78.4% (156/199) were on active ADT, and most were using a GnRH analog (80.1%; 125/156).
Most of patients were in palliative treatment (89.9%; 179/199). Also, 63.3% of our cohort died from COVID-19. Fortyeight patients under active ADT were pair matched against 48 controls (non-active ADT). All patients (199) were analyzed in the double robust model. ADT active use were not protective factor in both inverse-weight based propensity
score (OR 0.70, 95% CI 0.38–1.31, P = 0.263), and pair-matched propensity score (OR 0.67, 95% CI 0.27–1.63, P = 0.374)
models. We noticed a significant imbalance in the propensity score of patients in active and those in non-active ADT,
with important reductions in the differences after the adjustments.
Conclusions: The active use of ADT was not associated with a reduced risk of death in patients with COVID-19.
Keywords: COVID-19, Androgen antagonists, Androgen receptor antagonists, Antineoplastic agents
*Correspondence: jbcc@unicamp.br
1
Division of Oncology, Department of Anesthesiology, Oncology
and Radiology, School of Medical Sciences, State University of Campinas
(UNICAMP), Campinas, SP, Brazil
Full list of author information is available at the end of the article
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit